• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Senseonics offers equity grants under inducement plan

October 6, 2022 By Sean Whooley

Senseonics Eversense E3 Ascensia Diabetes Care
The Eversense E3 system. [Image from Ascensia/Senseonics]
Senseonics (NYSE:SENS) announced today that it granted six new non-executive employees stock options under an inducement plan.

Germantown, Maryland-based Senseonics granted the employees non-qualified stock options. The options allow them to purchase an aggregate of 78,000 shares of the company’s common stock. It represents an inducement for such employees to join the company, according to a news release.

The options have an exercise price of $1.34 per share. That marks the closing price of Senseonics common stock on the NYSE yesterday, Oct. 5, 2022. In each case, 25% of the shares underlying the options vest on the first anniversary of the employee’s start date. The remainder vest in monthly installments over the subsequent three-year period.

In all cases, the options remain contingent on such employee’s continued service with Senseonics at the applicable vesting date.

The continuous glucose monitor (CGM) maker also announced that it plans to participate in the upcoming Morgan Stanley Global Healthcare Conference in New York.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Funding Roundup, Patient Monitoring Tagged With: Senseonics

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS